Stroke is the leading cause of mortality and disability among adults in China and is associated with high incidence, disability, mortality and recurrence rates, as well as high financial costs.Among the types of stroke, Acute Ischemic Stroke ("AIS") accounts for approximately 70%[1] of stroke cases in China and has been associated with a 10% mortality rate within the first 90 days as well as disability rates in more than a third of patients.The National Health Commission ("NHC")'s Healthy China Action (2019-2030) aims to lower mortality rates from cardiovascular and neurovascular diseases to the region of 20%[2], and more recently, the Bureau of Medical Administration under China's National Health Commission has targeted to increase the rates of reperfusion therapy for acute cerebral infarctions[3].

Direct aspiration for AIS can achieve efficacious recanalization of neurovascular arteries, achieve timely reperfusion and improve prognosis, and has been globally recommended as a treatment approach.China's leading physician in the field, Dr. Miao Zhongrong, Professor of Interventional Neuroradiology, Neurosurgery, and Neurology and Head of the Department of Interventional Neuroradiology at Beijing Tiantan Hospital (Capital Medical University), commented, "Afentta has demonstrated shorter procedure times, higher recanalization rates, lower disability rates and lower incidence of arterial dissection, presenting a more efficacious, faster and safer treatment option in interventional thrombectomy."

The Afentta intracranial thrombectomy aspiration catheter is the flagship product developed by HeMo Bioengineering (China) Ltd and has achieved the milestone of being China's first domestically-produced aspiration catheter system. Dr. Jack Wang, HeMo's Founder and Chief Technology Officer, commented, "HeMo Bioengineering is committed to bringing together 'smart' resources to serve China's needs in the neurovascular interventional space.With our professional management team of industry veterans and our diversified and global research and education resources, we are well-positioned to continue delivering world-leading, reliable and innovative medical devices."

HeMo has entered into technology partnerships with U.S.-based Imperative Care, Inc. and Tsinghua University's Department of Chemical Engineering, and has embarked on clinical trial collaborations with Beijing Tiantan Hospital (Capital Medical University).HeMo has also obtained patent protections for the proprietary technologies associated with its aspiration catheter system.Moving forward, HeMo is committed to accelerating the rapid development of China and APAC markets' interventional domain.

About HeMo Bioengineering Ltd:

Headquartered in Singapore, HeMo Bioengineering Ltd ("HeMo") is a fast-growing medical device company focused on the R&D and production of innovative medical devices for treating stroke patients.HeMo's current suite of neuro interventional products covers ischemic stroke, haemorrhagic stroke and neuro access. HeMo also has a strong presence in China, with manufacturing facilities in Weihai, Shandong and sales offices in Beijing and Shanghai. With a robust and diversified pipeline of other vascular intervention products under development, HeMo is well positioned to become a leading, global platform company in vascular intervention.

Visit HeMo at http://www.hemocorp.com.

For enquiries, please e-mail [emailprotected].

SOURCE HeMo Bioengineering Ltd

Home

Follow this link:
Singapore-based HeMo Bioengineering Receives China's NMPA Approval for flagship Afentta(TM) Aspiration Catheter - PRNewswire